Marshall Wace
IMNM icon

Marshall Wace’s Immunome IMNM Stock Holding History

Marshall Wace’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
500,537
-980,251
-66% -$21M 0.01% 1014
2026
Q1 		$32.4M Buy
1,480,788
+743,672
+101% +$16.6M 0.03% 525
2025
Q4 		$15.8M Buy
737,116
+44,937
+6% +$789K 0.01% 713
2025
Q3 		$8.11M Sell
692,179
-605,573
-47% -$6.02M 0.01% 997
2025
Q2 		$12.1M Sell
1,297,752
-312,956
-19% -$2.57M 0.01% 772
2025
Q1 		$10.8M Buy
1,610,708
+394,526
+32% +$3.79M 0.01% 743
2024
Q4 		$12.9M Sell
1,216,182
-251,228
-17% -$3.04M 0.02% 703
2024
Q3 		$21.5M Sell
1,467,410
-245,915
-14% -$3.49M 0.03% 488
2024
Q2 		$20.7M Buy
1,713,325
+1,191,774
+229% +$18.6M 0.03% 488
2024
Q1 		$12.9M Buy
+521,551
New +$10.6M 0.02% 662
2022
Q1 		– Sell
-10,654
Closed -$138K – 3641
2021
Q4 		$138K Buy
10,654
+2,306
+28% +$41.1K ﹤0.01% 3290
2021
Q3 		$203K Buy
+8,348
New +$146K ﹤0.01% 2797

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Marshall Wace's IMNM Position: Q2 2026 in Review

Marshall Wace reduced its Immunome (IMNM) stake by 66% in Q2 2026, selling an estimated $21M and leaving 500,537 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #1014.

Marshall Wace first reported a position in IMNM in Q3 2021 and has held it in 12 quarters since. The position peaked at $32.4M in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Marshall Wace held 500,537 shares of Immunome worth $10.6M as of Q2 2026.
  • Marshall Wace sold 980,251 Immunome shares in Q2 2026, an estimated $21M.
  • Immunome made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1014 holding.
  • Marshall Wace first reported a position in Immunome in Q3 2021 and has held it in 12 quarters since.
  • Marshall Wace's Immunome position peaked at $32.4M in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.